Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
New York, New York, United States In 1992 was created Highbridge Capital Management, which is appeared as VC. The leading representative office of defined VC is situated in the New York. The fund was located in North America if to be more exact in United States.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the Highbridge Capital Management, startups are often financed by ProQuest Investments, Perceptive Advisors, OrbiMed. The meaningful sponsors for the fund in investment in the same round are Iroquois Capital, Nite Capital Management, Harbor View Advisors. In the next rounds fund is usually obtained by OrbiMed, Heights Capital Management, Fort Mason Capital.
The higher amount of exits for fund were in 2017. The top activity for fund was in 2005. Comparing to the other companies, this Highbridge Capital Management performs on 49 percentage points more the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.
The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. We can highlight the next thriving fund investment areas, such as Management Consulting, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Emergent Payments, Inseego, Strategic Data Corp. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
Besides them, we counted 22 critical employees of this fund in our database.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Datiotec Electronics | - |
| Hudson Bay Capital Management | New York, New York, United States |
| Huimei Capital | - |
| iSGS Investment Works | Chiyoda, Japan |
| Ledstiernan | Stockholm, Stockholm County, Sweden |
| National Cancer Research Institute | England, London, United Kingdom |
| TASC | Chantilly, United States, Virginia |
| The Hillman Group | Cincinnati, Ohio, United States |
| University of Auckland Inventors Fund | - |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Invacare | $5M | 23 Dec 2022 | Elyria, Ohio, United States | ||
Invacare | $18M | 03 Oct 2022 | Elyria, Ohio, United States | ||
Gamida Cell | $25M | 28 Sep 2022 | Jerusalem, Jerusalem District, Israel | ||
Starry | $150M | 29 Mar 2022 | Boston, Massachusetts, United States | ||
CompoSecure | $175M | 28 Dec 2021 | New Jersey, United States | ||
Urgently Roadside Assistance | $75M | 22 Dec 2021 | Virginia, United States | ||
BigBear.ai | $200M | 08 Dec 2021 | Columbia, Maryland, United States | ||
Lime | $418M | 04 Nov 2021 | San Francisco, California, United States | ||
Santhera Pharmaceuticals | $27M | 20 Sep 2021 | Basel-Country, Switzerland |
– Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today announced the sale of $75m of 5.875% exchangeable senior notes due in 2026 (the “notes”) to certain funds managed by Highbridge Capital Management, LLC.
– The proceeds from this sale of notes, together with the net proceeds of Gamida Cell’s sale of $75m of ordinary shares in December 2020, are expected to provide Gamida Cell with sufficient liquidity to fund the company’s operations into the second half of 2022. These capital infusions will be used to support manufacturing, regulatory and commercial development activities for omidubicel and to further the preclinical and clinical development of GDA-201.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
